This study reports outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning (RIC) in 186 patients with chronic myeloid leukaemia (CML) from the European Blood and Marrow Transplantation group. The median age was 50, 64% were in 1 st chronic phase (CP), CP2 13%, accelerated phase 17% and blast crises 6%. The median EBMT transplant score was 3. The day 100 transplantation related mortality (TRM) was 6.1% (CI: 3.4-11) but rose to 23.3% (CI: 14-27) at 2 years. Fludarabine, busulfan and anti-thymocyte globulin (Fd/Bu/ATG) was associated with the lowest TRM of 11.6% (CI: 4.7-11) at 1 year. Acute graft versus host disease (GvHD) grade II-IV occurred in 32% and chronic GvHD in 43% (extensive in 24%). ATG was associated with a lower incidence of cGvHD. The overall (OS) and progression free survivals (PFS) at 3 years were 58% (CI: 50-66) and 37% (CI: 30-45) respectively. Adverse OS was associated with advanced disease (RR 3.4). PFS was inferior in advanced disease (RR 2.7) and a trend to improved outcomes with Fd/Bu/ATG (RR 0.58). RIC allografts are feasible in CML in 1 st or 2 nd CP. Since no other RIC regimen demonstrated superiority Fd/Bu/ATG should be considered as baseline in future prospective trials.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has arguably been applied most successfully in the treatment of chronic myeloid leukaemia and remains, despite recent advances in therapy the most effective strategy for inducing durable molecular remission 1, 2 . The application of conventional myeloablative allo-HSCT has, however been limited by the age of the recipient and the availability of matched sibling or unrelated donors.
The original view that the allogeneic cells simply provided a source of tumour free stem cells has been superceded by the realization of the importance of allogeneic T cells in mediating graft versus leukaemia (GvL) effects. This immunological activity is now thought to be a primary mechanism by which allo-HSCT achieves its anti-leukaemic effect. The clinical responses seen with donor lymphocyte infusions are the clearest demonstration of the potency of this immune action 3 and this effect is particularly pronounced in CML 4, 5 .
Reduced intensity conditioning regimens, in contrast to conventional myeloablative strategies are less myelosuppressive but remain profoundly immunosuppressive [6] [7] [8] [9] [10] . Phase II studies have demonstrated that reliable and durable engraftment is possible in the majority of patients and the one year transplant related toxicity is in the range of 10-15% 8, [11] [12] [13] [14] . The long term anti-tumour effect
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Two studies have reported favourable outcomes using fludarabine (30mg/m 2 /d x5), busulfan 8mg/kg and anti-thymocyte globulin (ATG). Or and colleagues reported the outcome of 24 patients treated in first chronic phase (CP1). Overall survival and progression free survivals were estimated at 85% (CI 70-100%) at 5 years. The incidences of acute (grade II-IV) and chronic graft versus host disease (GvHD) were 75% and 55 % respectively but accounted for the only 3 deaths in this series. All patients were reported to be RT-PCR negative for BCR-ABL 15 . The second study reported similar outcomes for 15 patients in CP1 using an identical conditioning regimen 16 .
However good results are not universally seen with this regimen and transplant related complications remain an issue 17, 18 . There are also concerns the risk of disease relapse may be higher especially with more advance disease 19 .
The purpose of the present study was to estimate the efficacy of RIC allografts in CML in a nonselected patient population. This was performed by a retrospective analysis of patients reported to the Chronic Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT), which collects data from over 500 transplant centers in and beyond Europe.
Patients and Methods
This study was conducted on behalf of the Chronic Leukaemia Working Party of the EBMT and was performed in conjunction with a study of reduced intensity conditioning in myeloma. All EBMT centres report a minimal essential dataset into a central database. This database was interrogated and all EBMT centres that had reported more than 5 RIC allografts for CML and/or myeloma were contacted for additional data. This analysis is restricted to patients with CML. Informed consent was obtained locally in accordance with the principles laid out in the Declaration of Helsinki and according to the local regulations applicable at the time of transplant. Since 1st Jan 2003 the EBMT has required centres to confirm that written informed consent has been obtained prior to data acceptance for new patients and prior to accepting follow up data from previously transplanted patients. The definition of RIC allografts was determined by contributing centers and was based on current EBMT guidance. Patients who received regimens of equivalent or lower intensity to busulfan 8mg/kg were included in the study. Patients who had received total body radiotherapy were included provided the fractionated delivered dose was 6 Gy. The minimal data required for inclusion of a patient in the study were: age at transplant, diagnosis, number of prior transplants, disease status at transplant, HLA match of donor, conditioning regimen, remission Chimerism studies were performed in the most part by molecular methodologies (73%), by cytogenetics in 25% and in 1 patient both techniques. Chimerism analysis was reported in one patient on the basis of ABO group.
Definitions
Response was documented on or after day 100 post-transplant. Response was sub-classified as cytogenetic remission according to established criteria 20 or molecular remission (bcr-abl negativity)
where possible. This sub-classification of complete response was missing in 43 (23%) patients. .
Survival was measured in months and defined as the time from the date of transplantation until date of death from any cause or last follow up. Progression free survival was defined as the date of transplantation until date of progression or death from any cause, or last follow up. Transplant related mortality was defined as death due to any cause other than disease progression or relapse.
The disease phase at transplantation was defined locally. GvHD was classified according to established criteria 21, 22 
Statistical analysis
Probabilities of survival and progression free survival were calculated using the Kaplan-Meier method, whilst transplant related mortality and relapse were estimated using the cumulative incidence procedure. Univariate comparisons were made using the log-rank test and variables found to be significant at the p< 0.1 level were entered into a proportional hazards regression analysis using a backward stepping procedure. Comparisons between groups were made using the Chi-squared test for categorical data, and the Mann-Whitney test for continuous data. P-values are from two-sided tests with those <0.05 considered significant. Quoted confidence intervals refer to 95% boundaries.
Results
Between Jan 1994 and Oct 2002 data were collected on 221 transplants from 38 centres within the EBMT group. The minimum essential dataset was available for 186 patients from 33 centres and these patients form the basis for this study.
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From
Patient characteristics
The patient characteristics for all patients and the subset in CP1 are shown in Table 1 . Thirty one different chemotherapy and antibody regimens were used and are summarised in Table 2 . The majority were fludarabine based (84%) often combined with busulfan (56%). Cyclophosphamide and melphalan were used less frequently (23% and 12% respectively). The combination of fludarabine, busulfan and ATG (Fd/Bu/ATG) was used in 40% of patients whereas a low dose total body irradiation (TBI) regimen was only used in 16 Table 1 .
Engraftment and Chimerism
Engraftment occurred in 94% of the patients irrespective of the stem cell source. Secondary graft failure occurred in 3%. The median times to neutrophil (>0.5 x10 /l at all times and 11 % did not become thrombocytopenic (>50 x10 9 /l). Chimerism data were available for 163 patients: 73% achieved 100% donor chimerism and 77% greater than 95% donor chimerism at some time post-transplant.
On subsequent analyses these figures had fallen to 65% with 100% donor and 68% greater than 95% donor.
Graft versus Host Disease
Acute GvHD (aGvHD) occurred in 92 patients (49%) and of these 35 (19%) developed grade I, 40 (21%) grade II and 17 (9%) grade III-IV aGvHD. The use of alemtuzumab, ATG, the type GvHD prophylaxis or the use of peripheral blood versus bone marrow did not influence the incidence or severity of aGvHD. Chronic GVHD (cGvHD) was evaluable in 137 patients of whom 26 (19%) developed limited and 32 (23%) extensive cGvHD. In 3 patients the grade of cGvHD was not specified and 15 developed cGvHD, which subsequently resolved. The use of ATG significantly reduced the incidence of cGvHD (44% vs 72%, p=0.001). The use of alemtuzumab was of For personal use only. on November 12, 2017. by guest www.bloodjournal.org From borderline significance (39% vs 59% p=0.06). No effect of the use of peripheral blood or the GvHD prophylaxis regimen on the incidence or severity of cGVHD could be demonstrated.
Transplantation related mortality
The 100 day, 1 and 2 year TRM's were 3.8% (CI: 1.9-8), 13.3% (CI: 9-19.2) and 18.9% (CI: 14-26).
Factors associated with reduction in TRM were disease phase at time of transplantation , 11.6% vs. 20.3% for chronic phase and advanced phase at 1 year, respectively, (p=0.005, Figure 1 ) and the use of Fd/Bu/ATG in the conditioning regimen (yes 7.0% vs no 18.0%, p= 0.004). The use of busulfan alone was of borderline significance (p=0.076). In multivariate analysis advanced disease (RR 2.04, CI:1.05-3.98) and not receiving Fd/Bu/ATG (RR 2.46, CI 1.15-5.26) were associated with increased risks of TRM.. Development of grade III-IV aGvHD or.cGvHD were also associated with an increased TRM regardless of disease phase.
Response, Relapse and Progression Free Survival
Of the 186 patients, 10 were not evaluable for response due to early death. Overall 87% (152/172) of patients were in remission at the time of first report (on or around day 100 post transplant). Data on the use of molecular and cytogenetics to define remission are incomplete, however at least forty percent of patients had attained a molecular complete response (CR) and at least 62% a cytogenetic CR (Table 3) . When CP1 patients were analyzed separately then the overall response rate was 96% with molecular and cytogenetics CR's being achieved in at least 48% and 72%, respectively. The overall response rates in second chronic phase (CP2), accelerated phase and blast crises were 92%, 67% and 22% respectively. The median time to documentation of remission was 92 days.
Overall 72 patients relapsed with a cumulative probability of relapse of 47% at 3 years. The median time to progression has not been reached. Patients with more advanced disease were at higher risk of relapse at 68.6% and 68.7% for accelerated phase (AP) and blast crises (BC) respectively compared to 34.6% for CP1 and 45.4% for CP2. Other factors associated with an increased risk of relapse were the use of fludarabine + TBI and/or cylophosphamide whereas busulfan was associated with a decreased relapse risk. With respect to the use of lymphocyte depleting antibodies, alemtuzumab was associated with a higher relapse incidence (63%) at 2 years compared to ATG or no antibody (36.0% and 50.5% respectively, p=0.02). The factors that retained significance on multivariate analysis were transplantation for advanced phase disease (RR 3.73, CI 2.2-6.3 p<0.001, Figure 2 ) and the use of alemtuzumab (RR 2.82, CI 1.5-5.5, p=0.002).
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The median projected PFS was 15.6 months with a 3 year PFS of 33% (CI: 26-41, Figure 3 ).
Chronic phase disease was associated with superior PFS being 43% at 3 years (CI: 34-52). Other important factors were prior transplantation and the use of Fd/Bu/ATG for the conditioning. The effect, if any, of the use of alemtuzumab was difficult to evaluate as the number of patients receiving this drug was small. There was a trend towards an adverse effect (p=0.06, Table 4 ). On multivariate analysis transplantation in advanced phase disease retained significance for adverse outcome. The use of Fd/Bu/ATG was associated with a trend to improved outcome ( Table 5 ). The benefit of Fd/BU/ATG was more marked in patients in CP1 patients (RR 0.6 CI 0.3-0.9 p=0.03, Figure 4 ).
Donor Lymphocyte infusion and Imatinib
Donor lymphocyte infusions (DLI) were used in 50 patients (27%) with a median time to DLI of 6 months (30 days-2yrs). In 36 patients (74%) the indication for DLI was disease relapse. DLI was used pre-emptively in 6 (12%) patients and to increase the degree of donor chimerism in 7 (12%).
The median number of infusions was 2 (range 1-10) and the median cell dose for the final infusion (Table 4) . Of these factors transplantation in advanced disease phase retained significance on multivariate analysis ( Figure 5 ) with a trend to adverse outcome with prior transplantation (Table 5 ).
Outcome and EBMT transplantation risk score
Overall survival was also predicted by EBMT score (p=0.006). Patients with a score of 1-2, 3-4 and greater than 4 had an OS of 69% compared to 57% and 33% respectively ( Figure 6 ). EBMT scores 1-2, 3-4 and greater than 4 were also significant for PFS at 49% compared to 35% and 19%, respectively.
For
Discussion
Chronic myeloid leukemia is theoretically a difficult environment in which to achieve durable hematopoetic engraftment with reduced intensity conditioning, given the hypercellular nature of the pre transplantation marrow and the lack of any intensive prior chemotherapy. The sustained engraftment rate (91% including secondary graft failure) is somewhat lower than obtained with conventional conditioning but remains acceptable given that autologous reconstitution is the expected consequence of graft failure. Previous smaller studies 15, 16 have demonstrated similar engraftment rates but this is the largest study to date that shows that engraftment can be achieved using a variety of different conditioning regimens. The median times to neutrophil and platelet engraftment and the lack of severe neutropenia and thrombocytopenia in patients receiving PBSC grafts are consistent with previous reports 23, 24 . The attainment of full donor chimerism is important both in assuring stable and durable engraftment and also in providing a basis for the graft versus leukemia effect and subsequent immunotherapy. In this study full donor chimerism was achieved in the majority of patients. The results of chimerism at later time-points post-transplantation were only available in smaller proportion of patients so the observed fall in the level of donor chimerism may not be representative of the whole patient population.
Overall the transplant related mortality was low particularly in light of the median age and a median risk assessment score of 3. The day 100 TRM however substantially underestimates the risk of the procedure as the TRM continues to rise for at least the first two years. The association between increased TRM and disease phase is expected. The reason for the reduced TRM with the use Fd/Bu/ATG is less clear. In vivo T cell depletion with ATG may be relevant as the low TRM may be partially explained by the lower incidence of severe aGvHD (8% grade III-IV) Chronic GvHD was more prevalent possibly reflecting the delay in onset of GvHD which is apparent after RIC
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. As expected the development of extensive cGvHD was associated with an increase in TRM. In contrast to aGvHD the incidence of cGvHD was affected both by the use of ATG and alemtuzumab although the latter was of borderline significance.
For patients in CP1 or CP2 the overall survival was 69% and 57% respectively at 3 years. The outcome however for patients in AP or BC is inferior with 2 year OS of 24% and 8% respectively..
At 3 years the overall survivals of patients with scores of 1 and 2 at 69% are similar to those obtained by conventional transplantation at 80% and 70%
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. As there is uncertainty about the relapse risk with RIC these data do not provide any evidence of advantage to justify choosing a reduced intensity rather than a conventional approach in these groups. In contrast the 3 year survivals for patients with EBMT scores of 3, 4 and 5 were 67%, 42% and 35% compared to 55%, 45% and 27% (for score 5-7) for conventional transplants. Although long-term data with respect to disease free survivals are clearly not yet available, these results suggest that in the short-term RIC For personal use only. on November 12, 2017. by guest www.bloodjournal.org From transplantation may be the preferred option for patients with a higher EBMT transplantation score. This is of particular relevance at the present time as the encouraging early results of imatinib has led to a re-evaluation of the role of transplantation and a substantial reduction in numbers of patients transplanted 27 . The majority of patients are now only offered transplantation if imatinib has failed. These individuals will inevitably come to transplantation with higher risk scores due to their age, the delay from diagnosis to transplantation and possible advanced phase disease.
The overall remission rate was 87%. Data relating to more specific remission rates, i.e. molecular and/or cytogenetic remissions are difficult to obtain due to the different forms of assessment of remission in different centres. Relapse remains a significant problem in all disease phases. The type of conditioning does seem to impact on this risk with the highest relapse rates being seen after the use of alemtuzumab (76% at 2 years). The association between T cell depletion and disease relapse is well known 28 and the results with alemtuzumab are consistent with this. Of note however lymphocyte depletion with ATG did not have the same adverse outcome and it is unclear from this study whether this is due to the relative potency/dose or specificity of the drug. The use of fludarabine and TBI was also associated with poorer outcomes. Fludarabine and low dose TBI is one of the least intensive of the regimens used and this may be a factor in the poor outcomes seen. However, this observation needs to be interpreted with great caution as it is based on very small patient numbers. This group for example contained only 4 patients in CP1. For this reason FD+TBI was not included in the multivariate analysis. Fludarabine + TBI has been associated in one study with increased rate of graft failure, GvHD and TRM 29 however other groups report better results using this conditioning 10, 30 . The importance of the relative conditioning intensity remains an area of considerable uncertainty and although some of the more intensive of the RIC regimens report good outcomes in terms of disease control the benefit with respect to reduction in TRM is less clear 31 .
Whilst relapse is unwelcome, the use of DLI and/or imatinib can restore remissions. The limited data available here are consistent with published data on the efficacy of DLI for relapse 32 after allogeneic transplantation and with the limited data on the use of imatinib in this setting 33 . Given these options disease relapse may be a more acceptable risk in CML compared to other hematological malignancies.
In most series patients with unrelated donors have an unfavourable outcome. In this study survival of patients with unrelated BM/PBSC donors was not significantly inferior to that of patients with matched related donors. This is unlikely to be related to the use of RIC transplantation alone. First improvements in HLA typing and better supportive care have led to an improvement in unrelated transplant outcomes 34 . Second T cell depletion which is associated with a reduction in early transplant related mortality, was used in the majority of unrelated transplants. Finally the relatively small number of unrelated transplants might be insufficient to demonstrate any small differences.
No conditioning regimen demonstrated clear superiority. There was a trend towards improved outcomes with respect to PFS in this series in patients receiving Fd/Bu/ATG, although this did not retain significance on multivariate analysis for overall survival. Whilst it would be inappropriate to conclude that this is the optimal regimen, the use of this combination might form the basis of future prospective studies.
This is a retrospective registry based study, which documents outcomes being achieved with RIC allografts in CML in a representative cross-section of European transplant centres. It confirms the feasibility of RIC transplantation in CML and demonstrates efficacy particularly in CP1 or CP2, It also identifies good and poor risk factors and as such provides data for the rational design of the prospective studies which are now required.
results especially when performed in the early course of the disease. Table 3 Overall and best response at day 100 post RIC allograft according to disease phase at the time of transplant. 
